90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial?

European Journal of Cancer

Volumn 44, Issue 11, 2008, Pages 1536-1540

  Arkenau, Hendrik Tobias ^a   Olmos, David ^a   Ang, Joo Ern ^a   Barriuso, Jorge ^a   Karavasilis, Vasilios ^a   Ashley, Sue ^b   de Bono, Johann ^a   Judson, Ian ^a   Kaye, Stan ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b Royal Marsden Hospital   (United Kingdom)

Author keywords

90 Days mortality; Phase I trial; Prognostic factors; Survival

Indexed keywords

ALBUMIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE COUNT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; WELLBEING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CLINICAL TRIALS, PHASE I AS TOPIC; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 46049110497     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.04.017     Document Type: Article

References (11)

1. Roberts T.G., Goulart B.H., Squitieri L., et al. Trends in the risk and benefits to patients with cancer participating in phase-I clinical trials. JAMA 292 (2004) 2130-2140
2. Horstmann E., McCabe M.S., Grochow L., et al. Risks and benefits of phase-1 oncology trials, 1991 through 2002. New Engl J Med 352 (2005) 895-904
3. Sekine I., Yamamoto N., Kunitoh H., et al. Relationship between objective responses in phase-I trials and potential efficacy of non-specific cytotoxic investigational new drugs. Ann Oncol 13 (2002) 1300-1306
4. Arkenau H.T., Olmos D., Ang J.E., de Bono J., Judson I., and Kaye S. Clinical outcome and prognostic factors for patients treated within the context of a phase-I study: The Royal Marsden Hospital experience. Br J Cancer 98 (2008) 1029-1033
5. Bachelot T., Ray-Coquard I., Catimel G., et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase-I clinical trials. Ann Oncol 11 (2000) 151-156
6. Han C., Braybrooke J.P., Deplanque G., et al. Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 89 (2003) 1166-1171
7. Yamamoto N., Tamura T., Fukuoka M., and Saijo N. Survival and prognostic factors in lung cancer patients treated in phase-I trials: Japanese experience. Int J Oncol 15 (1999) 737-774
8. Arkenau HT, Barriuso J, Olmos D et al. Prospective validation of a prognostic score to improve patient selection for phase-I trials. In: Proc. ASCO; 2008 [abstr 2508].
9. Seidenfeld J., Horstmann E., Emanuel E.J., and Grady C. Participants in phase-I oncology research trials: are they vulnerable?. Arch Intern Med 168 (2008) 16-20
10. Connors T. Anticancer drug development: the way forward. Oncologist 1 (1996) 180-181
11. Penel N., Vanseymortier M., Bonneterre M.E., et al. Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs 26 1 (2008) 53-58